Involvement of AMPK and MAPK signaling during the progression of experimental autoimmune myocarditis in rats and its blockade using a novel antioxidant

Experimental and Molecular Pathology

Volumn 93, Issue 2, 2012, Pages 183-189

  Arumugam, Somasundaram ^a   Thandavarayan, Rajarajan A ^a   Veeraveedu, Punniyakoti T ^b   Giridharan, Vijayasree V ^a   Soetikno, Vivian ^a   Harima, Meilei ^a   Suzuki, Kenji ^c   Nagata, Masaki ^c   Tagaki, Ritsuo ^c   Kodama, Makoto ^c   Watanabe, Kenichi ^a  

^a NIIGATA UNIVERSITY OF PHARMACY AND APPLIED LIFE SCIENCES   (Japan)

^b OSAKA UNIVERSITY   (Japan)

^c NIIGATA UNIVERSITY GRADUATE SCHOOL OF MEDICAL AND DENTAL SCIENCES   (Japan)

Author keywords

AMPK; Antioxidant; Edaravone; MAPK; PI 3K Akt signaling

Indexed keywords

CANDESARTAN; GLYCERALDEHYDE 3 PHOSPHATE DEHYDROGENASE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE ALPHA; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; MITOGEN ACTIVATED PROTEIN KINASE P38; NORPHENAZONE; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; PROTEIN KINASE C ALPHA; PROTEIN KINASE C BETA; PROTEIN KINASE C BETA1; PROTEIN KINASE C BETA2; PROTEIN KINASE C DELTA; STRESS ACTIVATED PROTEIN KINASE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIOXIDANT ACTIVITY; ARTICLE; AUTOIMMUNE DISEASE; CELL INFILTRATION; CONGESTIVE CARDIOMYOPATHY; CONTROLLED STUDY; DISEASE COURSE; ENZYME ACTIVATION; ENZYME ACTIVITY; EXPERIMENTAL AUTOIMMUNE MYOCARDITIS; HEART HYPERTROPHY; HEART PROTECTION; HISTOPATHOLOGY; IMMUNOHISTOCHEMISTRY; INFLAMMATORY CELL; MALE; MYOCARDITIS; NONHUMAN; OXIDATIVE STRESS; PROTEIN EXPRESSION; RAT; SIGNAL TRANSDUCTION; UPREGULATION; WESTERN BLOTTING;

ANIMALS; ANTIPYRINE; AUTOIMMUNE DISEASES; DISEASE MODELS, ANIMAL; DISEASE PROGRESSION; FREE RADICAL SCAVENGERS; HEART; ISOENZYMES; MALE; MITOGEN-ACTIVATED PROTEIN KINASE KINASES; MYOCARDITIS; MYOCARDIUM; OXIDATIVE STRESS; PHOSPHATIDYLINOSITOL 3-KINASE; PHOSPHORYLATION; PROTEIN KINASES; PROTO-ONCOGENE PROTEINS C-AKT; RATS; RATS, INBRED LEW; SIGNAL TRANSDUCTION;

RATTUS;

EID: 84862129851     PISSN: 00144800     EISSN: 10960945     Source Type: Journal    
DOI: 10.1016/j.yexmp.2012.04.012     Document Type: Article

References (40)

1. Baughman K.L. Diagnosis of myocarditis: death of Dallas criteria. Circulation 2006, 113:593-595.
2. Bowling N., Walsh R.A., Song G., Estridge T., Sandusky G.E., Fouts R.L., Mintze K., Pickard T., Roden R., Bristow M.R., Sabbah H.N., Mizrahi J.L., Gromo G., King G.L., Vlahos C.J. Increased protein kinase C activity and expression of Ca2+-sensitive isoforms in the failing human heart. Circulation 1999, 99:384-391.
3. Braz J.C., Bueno O.F., De Windt L.J., Molkentin J.D. PKC alpha regulates the hypertrophic growth of cardiomyocytes through extracellular signal-regulated kinase1/2 (ERK1/2). The Journal of Cell Biology 2002, 156:905-919.
4. Cooper L.T. Myocarditis. The New England Journal of Medicine 2009, 360:1526-1538.
5. Dolinsky V.W., Dyck J.R. Role of AMP-activated protein kinase in healthy and diseased hearts. American Journal of Physiology. Heart and Circulatory Physiology 2006, 291:H2557-H2569.
6. Gruson D., Ginion A., Decroly N., Lause P., Vanoverschelde J.L., Ketelslegers J.M., Bertrand L., Thissen J.P. Urotensin II induction of adult cardiomyocytes hypertrophy involves the Akt/GSK-3beta signaling pathway. Peptides 2010, 31:1326-1333.
7. Hahn H.S., Marreez Y., Odley A., Sterbling A., Yussman M.G., Hilty K.C., Bodi I., Liggett S.B., Schwartz A., Dorn G.W. Protein kinase Calpha negatively regulates systolic and diastolic function in pathological hypertrophy. Circulation Research 2003, 93:1111-1119.
8. Han J., Molkentin J.D. Regulation of MEF2 by p38 MAPK and its implication in cardiomyocyte biology. Trends in Cardiovascular Medicine 2000, 10:19-22.
9. Hickson-Bick D.L., Buja L.M., McMillin J.B. Palmitate-mediated alterations in the fatty acid metabolism of rat neonatal cardiac myocytes. Journal of Molecular and Cellular Cardiology 2000, 32:511-519.
10. Jalili T., Takeishi Y., Song G., Ball N.A., Howles G., Walsh R.A. PKC translocation without changes in Galphaq and PLC-beta protein abundance in cardiac hypertrophy and failure. The American Journal of Physiology 1999, 277:H2298-H2304.
11. Jones R.G., Plas D.R., Kubek S., Buzzai M., Mu J., Xu Y., Birnbaum M.J., Thompson C.B. AMP-activated protein kinase induces a p53-dependent metabolic checkpoint. Molecular Cell 2005, 18:283-293.
12. Kodama M., Matsumoto Y., Fujiwara M., Masani F., Izumi T., Shibata A. A novel experimental model of giant cell myocarditis induced in rats by immunization with cardiac myosin fraction. Clinical Immunology and Immunopathology 1990, 57:250-262.
13. Kodama M., Hanawa H., Saeki M., Hosono H., Inomata T., Suzuki K., Shibata A. Rat dilated cardiomyopathy after autoimmune giant cell myocarditis. Circulation Research 1994, 75:278-284.
14. Kudo N., Barr A.J., Barr R.L., Desai S., Lopaschuk G.D. High rates of fatty acid oxidation during reperfusion of ischemic hearts are associated with a decrease in malonyl-CoA levels due to an increase in 5?-AMP-activated protein kinase inhibition of acetyl-CoA carboxylase. Journal of Biological Chemistry 1995, 270:17513-17520.
15. Li M., Georgakopoulos D., Lu G., Hester L., Kass D.A., Hasday J., Wang Y. p38 MAP kinase mediates inflammatory cytokine induction in cardiomyocytes and extracellular matrix remodeling in heart. Circulation 2005, 111:2494-2502.
16. MacRae C.A., Ghaisas N., Kass S., Donnelly S., Basson C.T., Watkins H.C., Anan R., Thierfelder L.H., McGarry K., Rowland E. Familial hypertrophic cardiomyopathy with Wolff-Parkinson-White syndrome maps to a locus on chromosome 7q3. The Journal of Clinical Investigation 1995, 96:1216-12120.
17. Maruyama R., Uno Y., Arai M., Takemura G., Fujiwara H. Edaravone reduces myocardial infarct size and improves cardiac function and remodelling in rabbits. Clinical and Experimental Pharmacology & Physiology 2006, 33:1035-1041.
18. McKinsey T.A., Zhang C.L., Olson E.N. Control of muscle development by dueling HATs and HDACs. Current Opinion in Genetics & Development 2001, 11:497-504.
19. Meier M., King G.L. Protein kinase C activation and its pharmacological inhibition in vascular disease. Vascular Medicine 2000, 5:173-185.
20. Meisse D., Van de Casteele M., Beauloye C., Hainault I., Kefas B.A., Rider M.H., Foufelle F., Hue L. Sustained activation of AMP-activated protein kinase induces c-Jun N-terminal kinase activation and apoptosis in liver cells. FEBS Letters 2002, 526:38-42.
21. Nagoshi T., Yoshimura M., Rosano G.M., Lopaschuk G.D., Mochizuki S. Optimization of cardiac metabolism in heart failure. Current Pharmaceutical Design 2011, (Epub ahead of print, PMID: 21933140).
22. Purcell N.H., Tang G., Yu C., Mercurio F., DiDonato J.A., Lin A. Activation of NF-kappa B is required for hypertrophic growth of primary rat neonatal ventricular cardiomyocytes. Proc Natl Acad Sci U S A. 2001, 98:6668-6673.
23. Ramirez M.T., Sah V.P., Zhao X.L., Hunter J.J., Chien K.R., Brown J.H. The MEKK-JNK pathway is stimulated by a1-adrenergic receptor and ras activation and is associated with in vitro and in vivo cardiac hypertrophy. Journal of Biological Chemistry 1997, 272:14057-14061.
24. Riad A., Unger D., Du J., Westermann D., Mohr Z., Sobirey M., Dorenkamp M., Schultheiss H.P., Tschope C. Chronic inhibition of p38MAPK improves cardiac and endothelial function in experimental diabetes mellitus. European Journal of Pharmacology 2007, 554:40-45.
25. Rigor D.L., Bodyak N., Bae S., Choi J.H., Zhang L., Ter-Ovanesyan D., He Z., McMullen J.R., Shioi T., Izumo S., King G.L., Kang P.M. Phosphoinositide 3-kinase Akt signaling pathway interacts with protein kinase C?2 in the regulation of physiologic developmental hypertrophy and heart function. American Journal of Physiology. Heart and Circulatory Physiology 2009, 18:275-283.
26. Rohini A., Agrawal N., Koyani C.N., Singh R. Molecular targets and regulators of cardiac hypertrophy. Pharmacological Research 2010, 61:269-280.
27. Sambandam N., Lopaschuk G.D. AMP-activated protein kinase (AMPK) control of fatty acid and glucose metabolism in the ischemic heart. Progress in Lipid Research 2003, 42:238-256.
28. Schonwasser D.C., Marais R.M., Marshall C.J., Parker P.J. Activation of the mitogen-activated protein kinase/extracellular signal-regulated kinase pathway by conventional, novel, and atypical protein kinase C isotypes. Molecular and Cellular Biology 1998, 18:790-798.
29. Shimazaki H., Watanabe K., Veeraveedu P.T., Harima M., Thandavarayan R.A., Arozal W., Tachikawa H., Kodama M., Aizawa Y. The antioxidant edaravone attenuates ER-stress-mediated cardiac apoptosis and dysfunction in rats with autoimmune myocarditis. Free Radical Research 2010, 44:1082-1090.
30. Sukumaran V., Watanabe K., Veeraveedu P.T., Thandavarayan R.A., Gurusamy N., Ma M., Yamaguchi K., Suzuki K., Kodama M., Aizawa Y. Telmisartan, an angiotensin-II receptor blocker ameliorates cardiac remodeling in rats with dilated cardiomyopathy. Hypertension Research 2010, 33:695-702.
31. Tada S., Nakamoto N., Kameyama K., Tsunematsu S., Kumagai N., Saito H., Ishii H. Clinical usefulness of edaravone for acute liver injury. Journal of Gastroenterology and Hepatology 2003, 18:851-857.
32. Taha M., Lopaschuk G.D. Alterations in energy metabolism in cardiomyopathies. Annals of Medicine 2007, 39:594-607.
33. Thandavarayan R.A., Watanabe K., Ma M., Gurusamy N., Veeraveedu P.T., Konishi T., Zhang S., Muslin A.J., Kodama M., Aizawa Y. Dominant-negative p38alpha mitogen-activated protein kinase prevents cardiac apoptosis and remodeling after streptozotocin-induced diabetes mellitus. American Journal of Physiology. Heart and Circulatory Physiology 2009, 297:H911-H919.
34. Thandavarayan R.A., Watanabe K., Sari F.R., Ma M., Lakshmanan A.P., Giridharan V.V., Gurusamy N., Nishida H., Konishi T., Zhang S., Muslin A.J., Kodama M., Aizawa Y. Modulation of doxorubicin-induced cardiac dysfunction in dominant-negative p38? mitogen-activated protein kinase mice. Free Radical Biology & Medicine 2010, 49:1422-1431.
35. Tsujimoto I., Hikoso S., Yamaguchi O., Kashiwase K., Nakai A., Takeda T., Watanabe T., Taniike M., Matsumura Y., Nishida K., Hori M., Kogo M., Otsu K. The antioxidant edaravone attenuates pressure overload-induced left ventricular hypertrophy. Hypertension 2005, 45:921-926.
36. Veeraveedu P.T., Watanabe K., Ma M., Thandavarayan R.A., Palaniyandi S.S., Yamaguchi K., Suzuki K., Kodama M., Aizawa Y. Comparative effects of torasemide and furosemide in rats with heart failure. Biochemical Pharmacology 2008, 75:649-659.
37. Venema R.C., Kuo J.F. Protein kinase C-mediated phosphorylation of troponin I and C-protein in isolated myocardial cells is associated with inhibition of myofibrillar actomyosin MgATPase. Journal of Biological Chemistry 1993, 268:2705-2711.
38. Watanabe K., Thandavarayan R.A., Harima M., Sari F.R., Gurusamy N., Veeraveedu P.T., Mito S., Arozal W., Sukumaran V., Laksmanan A.P., Soetikno V., Kodama M., Aizawa Y. Role of differential signaling pathways and oxidative stress in diabetic cardiomyopathy. Current Cardiology Reviews 2010, 6:280-290.
39. Yamaguchi K., Ogita K., Nakamura S., Nishizuka Y. The protein kinase C isoforms leading to MAP-kinase activation in CHO cells. Biochemical and Biophysical Research Communications 1995, 210:639-647.
40. Zhu W.Z., Zheng M., Koch W.J., Lefkowitz R.J., Kobilka B.K., Xio R.P. Dual modulation of cell survival and cell death by beta(2)-adrenergic signaling in adult mouse cardiac myocytes. Proceedings of the National Academy of Sciences of the United States of America 2001, 98:1607-1612.